

**IMPROVEMENT OF LOVASTATIN PRODUCTION by *Fusarium*
pseudocircinatum IBRL B3-4 via SOLID SUBSTRATE
FERMENTATION**

by

SYARIFAH AB RASHID

**Thesis submitted in fulfillment of the requirements for the degree of
Doctor of Philosophy**

AUGUST 2015

ACKNOWLEDGEMENT

In the name of Allah, The Most Merciful and The Most Gracious

To those individuals without whom I would not be penning these words in the first place, million thanks:

To Professor Dr Hajah Darah Ibrahim, my main supervisor, for her guidance from the early stage of the research until the thesis writing phase. She did inspire and impress me in her own way not only as a supervisor but also as a mother, advisor, spirit booster and even a friend. Thank you for all the chances and trust that you gave me. I really did learn a lot from you, really a lot.

To my co-supervisor, Dr Nyoman, to whom I am particularly grateful for guiding me from far away in Bandung, Indonesia. Thank you for your ideas mostly during the turbulent times. Also, special thanks to Malaysian Ministry of Education for the sponsorship under MyBrain15 program and also Ministry of Higher Education for research grant (Postgraduate Research *Grant* Scheme) awarded.

I also would like to express my gratitude towards staff of School Biological Sciences, School of Pharmaceutical Sciences, School of Chemistry, USM Drug Centre and USM Animal Research and Service Centre especially to Professor Baharuddin Salleh, Dr Latifah, Dr Shaida Fariza, Dr Ooi, Dr Isma Suzyta, Dr Ahmad Makaleh, Professor Baharuddin Saad, Puan Melati, Encik Yusuf, Mamu, Encik Hilman, Encik Rosli, Encik Kamarudin, Puan Jamilah, Encik Johari, Encik Rizal, Puan Faizah, Puan Azliza, Cik Shafiqah and Puan Shafawati, for providing the unconditional help.

Finally, to those I hold closest to my heart, my family and friends, whose understandings enlighten my way. To Mama (Nik Zabidah Nik Ab Razak) and Abah (Ab Rashid Ali), thank you for the sacrifices and encouragement that both of you done throughout my life. To my friends, thank you for all the sweet memories and believing in me when I myself did not. I am no one without Allah and those good people I mentioned above.

Lots of love,

SYARIFAH AB RASHID

TABLE OF CONTENTS		Page
Acknowledgements		ii
Table of Contents		iv
List of Tables		xiii
List of Figures		xv
List of Plates		xix
List of Symbols and Abbreviations		xx
List of Publications and Conferences		xxii
Abstrak		xxiii
Abstract		xxvi
CHAPTER 1	INTRODUCTION	1
1.1	Hypercholesterolemia versus its reversal agent	1
1.2	Fermentation and idiolites perspectives	2
1.3	Lovastatin in action	2
1.4	Rationales of study and objectives	4
CHAPTER 2	LITERATURE REVIEW	9
2.1	Agricultural crops in Malaysia: Rice processing and its byproduct	9
2.2	Cholesterol: a review	10
2.2.1	Biomedical applications of lovastatin	11
2.2.1.1	The triumph of lovastatin in heart disease	12
2.3	Statins	13
2.3.1	Back to the past: the historical statins	13
2.3.2	Biosynthesis of lovastatin	15
2.3.3	Lovastatin in SSF	16
2.4	Solid substrate fermentation (SSF) and its consideration factors	19
2.4.1	Definition of SSF	19
2.4.2	Rationale of filamentous fungi selection	20
2.4.2.1	<i>Fusarium</i> sp. and its major mycotoxins	22

	2.4.3 Substrates suitability	28
	2.4.4 Roles of particle size in SSF	30
	2.4.5 Moisture content or water activity (a_w) rules	31
	2.4.6 pH and its control	32
	2.4.7 The influence of temperature	33
	2.4.8 The importance of aeration in SSF	34
	2.4.9 Effect of carbon and nitrogen	34
	2.4.10 Scale up system: bioreactors	35
2.5	Concluding remarks	38
CHAPTER 3	GENERAL MATERIALS AND METHODS	40
3.1	Substrates and fungi	40
	3.1.1 Sources	40
	3.1.2 Purification and maintenance of fungi	40
	3.1.3 Inoculum preparation via direct counting using a haemocytometer	41
3.2	Analysis	41
	3.2.1 Extraction of fermented solid substrates	41
	3.2.2 Lovastatin estimation	42
	3.2.3 Fungal growth determination	43
	3.2.4 Statistical analysis	45
CHAPTER 4	ISOLATION, SCREENING AND IDENTIFICATION OF LOVASTATIN LATENT PRODUCERS VIA MORPHOLOGICAL AND MOLECULAR APPROACHES	46
4.1	Introduction	46
4.2	Materials and Methods	47
	4.2.1 Isolation of potential lovastatin producer	47
	4.2.2 Chemical compositions analysis	49
	4.2.2.1 Moisture content	49
	4.2.2.2 Determination of crude protein	49
	4.2.2.3 Ash content	50

4.2.2.4	Determination of crude lipid	51
4.2.2.5	Crude fiber content	52
4.2.2.6	Determination of carbohydrate	53
4.2.3	Primary screening of lovastatin producers	53
4.2.3.1	Solid substrate fermentation compositions	53
4.2.3.2	Thin layer chromatography	54
4.2.4	Secondary screening via high performance liquid chromatography	55
4.2.5	Identification of potential lovastatin producer	56
4.2.5.1	Colony and structural morphologies	56
4.2.5.1(a)	Macroscopic observation of IBRL B3-4	56
4.2.5.1(b)	Microscopic observation of IBRL B3-4: Light microscope and Scanning Electron Microscope	57
4.2.5.2	The genus and species confirmation by molecular approach	58
4.2.5.2(a)	Freeze drying method for fungal preparation	58
4.2.5.2(b)	Extraction of dried IBRL 3-4 isolate sample	58
4.2.5.2(c)	Polymerase chain reaction (PCR) amplification and DNA sequencing of Translation Elongation Factor-1 α gene (TEF-1 α)	59
4.2.5.2(d)	PCR products purification	60
4.2.5.2(e)	TEF-1 α gene sequence analysis	61
4.3	Results and Discussion	61
4.3.1	Evaluation of nutrients compositions in rice bran and brown rice	61
4.3.2	Primary and secondary screenings of lovastatin producers on TLC plate and HPLC analysis	63
4.3.3	Identification of IBRL B3-4	68
4.3.3.1	Macroscopic observation	68
4.3.3.2	Microscopic observation: Characters on CLA	72

	and SNA	
	4.3.3.3 Molecular confirmation of fungal genera	79
4.4	Conclusion	84
CHAPTER 5	IMPROVEMENT OF PHYSICAL AND CHEMICAL PARAMETERS AND THEIR EFFECTS TOWARD LOVASTATIN PRODUCTION IN A FLASK SYSTEM	85
5.1	Introduction	85
5.2	Materials and Methods	87
	5.2.1 Microorganisms, inoculum and substrate preparations	87
	5.2.2 Influence of different organic solvents towards lovastatin recovery	87
	5.2.3 Process parameters improvement	87
	5.2.3.1 Time course profile of lovastatin synthesis before physical parameters improvement in flask system	88
	5.2.3.2 Influence of physical parameters on lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4	88
	5.2.3.2(a) Effect of substrate size	88
	5.2.3.2(b) Effect of different percentage of moisture content	89
	5.2.3.2(c) Effect of surroundings temperature	89
	5.2.3.2(d) Effect of inoculum size	90
	5.2.3.2(e) Effect of initial pH	90
	5.2.3.2(f) Effect of substrate quantity	90
	5.2.3.2(g) Effect of mixing frequency	91
	5.2.3.3 Time course profile of lovastatin synthesis after physical parameters improvement	91
	5.2.3.4 The influence of chemical parameters on lovastatin production by <i>F. pseudocircinatum</i>	92

	IBRL B3-4	
	5.2.3.4(a) Effect of carbon sources supplementation	92
	5.2.3.4(b) Effect of nitrogen sources supplementation	93
	5.2.3.4(c) Effect of mineral addition	94
	5.2.3.5 Time course profile of lovastatin production after chemical parameters improvement	94
	5.2.4 Analysis	95
	5.2.4.1 Extraction of fermented solid substrates	95
	5.2.4.2 Lovastatin estimation	95
	5.2.4.3 Fungal growth determination	95
	5.2.4.4 Statistical analysis	95
5.3	Results and Discussion	96
	5.3.1 Organic solvents extraction	96
	5.3.2 Improvement of physical and chemical parameters on lovastatin synthesis by <i>F. pseudocircinatum</i> IBRL B3-4	100
	5.3.2.1 Time course profile of lovastatin production before physical parameters improvement	100
	5.3.2.1(a) Effect of substrate size on lovastatin production	102
	5.3.2.1(b) Effect of moisture content on lovastatin production	105
	5.3.2.1(c) Effect of temperature on lovastatin production	107
	5.3.2.1(d) Effect of inoculum size on lovastatin production	109
	5.3.2.1(e) Effect of pH on lovastatin production	112
	5.3.2.1(f) Effect of substrate quantity on lovastatin production	114
	5.3.2.1(g) Effect of mixing frequency on lovastatin production	116
	5.3.2.2 Time course profile of lovastatin synthesis after physical parameters improvement	118

	5.3.2.3 Influence of chemical parameters on lovastatin production and growth of <i>F. pseudocircinatum</i> IBRL B3-4	121
	5.3.2.3(a) Effect of carbon sources	121
	5.3.2.3(b) Effect of nitrogen sources	125
	5.3.2.3(c) Effect of minerals salt addition	129
	5.3.2.4 Time course profile of lovastatin synthesis after chemical parameters improvement	133
5.4	Conclusion	139
CHAPTER 6	LOVASTATIN PRODUCTION BY <i>F. pseudocircinatum</i> IBRL B3-4 IN A LABORATORY SCALE SYSTEM AND PURIFICATION OF LOVASTATIN PRODUCED UNDER SSF	140
6.1	Introduction	140
6.2	Materials and Methods	142
	6.2.1 Preparations of microorganism and inoculums	142
	6.2.2 Basal composition of SSF in a tray system	142
	6.2.3 Parameter improvement process in a tray system	143
	6.2.3.1 Profiles of growth and lovastatin production before improvement	143
	6.2.3.2 Effect of substrate size	144
	6.2.3.3 Effect of moisture content	144
	6.2.3.4 Effect of incubation temperature	145
	6.2.3.5 Effect of inoculum size	145
	6.2.3.6 Effect of initial pH	145
	6.2.3.7 Effect of mixing frequency	146
	6.2.3.8 Time course profile after physical parameters improvement	146
	6.2.4 Purification of lovastatin via chromatographic procedure	146
	6.2.4.1 Open column chromatography	146
	6.2.4.1(a) Sample preparation	146

	6.2.4.1(b) Column packing	147
	6.2.4.1(c) Sample loading and fraction collection	147
	6.2.4.2 Preparative thin layer chromatography	148
	6.2.4.3 High performance liquid chromatography	149
	6.2.5 Analysis	149
	6.2.5.1 Extraction of lovastatin	149
	6.2.5.2 Lovastatin estimation	149
	6.2.5.3 Fungal growth determination	149
	6.2.5.4 Statistical analysis	149
6.3	Results and Discussion	150
	6.3.1 Parameter improvement process in a tray system	150
	6.3.1.1 Time course profiles before physical parameters improvement	150
	6.3.1.1(a) Effect of substrate sizes	154
	6.3.1.1(b) Effect of moisture content	157
	6.3.1.1(c) Effect of temperature	159
	6.3.1.1(d) Effect of inoculum size	162
	6.3.1.1(e) Effect of initial pH	164
	6.3.1.1(f) Effect of mixing frequency	166
	6.3.1.2 Time course profile after physical parameters improvement	168
	6.3.2 Comparison of lovastatin production and fungal growth between flask and tray systems	169
	6.3.3 Purification of lovastatin	177
	6.3.3.1 Purification by open column chromatography	177
	6.3.3.2 Purification via TLC and HPLC	181
6.4	Conclusion	185
CHAPTER 7	PRELIMINARY STUDIES OF FRACTIONAL LOVASTATIN ON BRINE SHRIMP AND LABORATORY RATS	186
7.1	Introduction	186
7.2	Materials and Methods	187

	7.2.1	Mycotoxins production	187
	7.2.1.1	Mycotoxins analysis	188
	7.2.1.1(a)	Moniliformin (MON)	188
	7.2.1.1(b)	Beauvericin (BEA)	190
	7.2.1.1(c)	Fumonisin B ₁ (FUM)	191
	7.2.2	Lethality test of fractional lovastatin on brine shrimp	192
	7.2.2.1	Hatching brine shrimp	192
	7.2.2.2	Fractional lovastatin preparation	193
	7.2.2.3	Brine shrimp test	193
	7.2.2.4	Determination of lethal concentration (LC ₅₀)	194
	7.2.3	Application of fractional lovastatin towards rats	194
	7.2.3.1	Administration of lovastatin	194
	7.2.3.2	Cholesterol diet versus standard diet	195
	7.2.3.3	Sprague Dawley grouping	195
	7.2.3.4	Cholesterol test	196
	7.2.3.5	Cholesterol analysis via colorimetric method	196
	7.2.3.5(a)	Standard preparation	196
	7.2.3.5(b)	Cholesterol sample preparation	197
	7.2.4	Statistical analysis	198
7.3		Results and Discussion	198
	7.3.1	Mycotoxins produced by <i>F. pseudocircinatum</i> IBRL B3-4	198
	7.3.2	Toxicity test on brine shrimp	203
	7.3.3	Cholesterol lowering effect of fractional lovastatin on Sprague Dawley rats	205
	7.3.3(a)	Growth pattern of rats under fractional lovastatin treatment	205
	7.3.3(b)	HDL and LDL level in Sprague Dawley	209
7.4		Conclusion	217
CHAPTER 8		SUMMARY AND GENERAL CONCLUSION	218
8.1		Recommendations and suggestions	221

REFERENCES	222
APENDICES	244

LIST OF TABLES		Page
Table 4.1	List of isolation locations and filamentous fungi codes lists	48
Table 4.2	The PCR thermal cycles applied for TEF-1 α amplification	60
Table 4.3	The chemical components in rice bran and brown rice (%)	62
Table 4.4	Double screening programmes in tracing lovastatin latent producers	64
Table 4.5	Other potential lovastatin producers obtained by different researchers	68
Table 4.6	Colony morphology of <i>Fusarium</i> species on PDA	74
Table 4.7	Structural morphologies of related <i>Fusarium</i> sp with IBRL B3-4 isolate	77
Table 4.8	The outcomes of sequence alignment in Fusarium-ID and GenBank (NCBI)	81
Table 5.1	Lovastatin recovery by various solvents	100
Table 5.2	Summary for the optimal physical parameters gained by researchers using various filamentous fungi via SSF system	120
Table 5.3	Carbon sources effect towards lovastatin production by various filamentous fungi in SSF system	125
Table 5.4	Various nitrogen sources which potentially can induce lovastatin production	129
Table 5.5	Mineral salts effect on lovastatin production obtained by different researchers	133

Table 5.6	Comparison of lovastatin production using various filamentous fungi	136
Table 6.1	Comparison of lovastatin productivity produced via SSF in flask and scale up systems	172
Table 6.2	Comparisons of chromatographic purification	181
Table 7.1	Preparation of fractional lovastatin for toxicity test	193
Table 7.2	Formulation for Reaction Mix solution	197
Table 7.3	Initial and final body weight of Sprague Dawley rats	206
Table 7.4	HDL and LDL levels in female Sprague Dawley prior to doses treatment	211
Table 7.5	HDL and LDL levels in male Sprague Dawley prior to doses treatment	211
Table 7.6	HDL and LDL levels in female under different doses treatment	212
Table 7.7	HDL and LDL levels in male after been treated with different doses of fractional lovastatin	213
Table 7.8	Percentage reduction of blood cholesterol level by <i>Laetisporus</i> sp. extract and commercial lovastatin product compared to control	215
Table 7.9	Fungi as cholesterol lowering agent in rats	216
Table 8.1	Lovastatin production of <i>F. pseudocircinatum</i> IBRL B3-4 before and after improvement in flask and tray systems	219

LIST OF FIGURES		Page
Figure 2.1	Different structures of natural, semisynthetic and synthetic statins and its similarity with HMG portion of HMG CoA reductase	17
Figure 2.2	Biosynthesis pathway for lovastatin generation in simplified scheme.	18
Figure 2.3	The illustrations of filamentous fungi growth invading the substrate matrix during fermentation process	21
Figure 2.4	The skeleton structure of moniliformin	23
Figure 2.5	The structure of fumonisin	25
Figure 2.6	Structure of cyclic hexadepsipeptide beauvericin and enniatins	27
Figure 2.7	Structure of zearalenone	28
Figure 2.8	Various types of bioreactors for SSF system application	37
Figure 4.1	DNA purification of the TEF-1 α of IBRL B3-4	80
Figure 4.2	The consensus sequences of IBRL B3-4	80
Figure 5.1	Effect of solvents on lovastatin production	96
Figure 5.2	Production of lovastatin before physical parameters improvement	101
Figure 5.3	Effect of different substrate particle sizes towards lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4.	103
Figure 5.4	Influence of initial moisture content on lovastatin production	106
Figure 5.5	Effect of temperature towards lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4	109

Figure 5.6	Effect of inoculum size on lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4	111
Figure 5.7	Effect of pH towards lovastatin production	113
Figure 5.8	Effect of substrate quantity on lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4	115
Figure 5.9	Effect of mixing frequency towards lovastatin production	117
Figure 5.10	Lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4 after physical improvement	119
Figure 5.11	Effect of different carbon sources towards lovastatin titer	123
Figure 5.12	Effect of various levels of sucrose on lovastatin production in SSF	123
Figure 5.13	Effect of different nitrogen sources towards lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4	126
Figure 5.14	Effect of different concentrations of yeast extract on the production of lovastatin	128
Figure 5.15	Effect of different mineral salts on lovastatin production by <i>F. pseudocircinatum</i> IBRL B3-4	130
Figure 5.16	Effect of calcium chloride on lovastatin production	131
Figure 5.17	Lovastatin production after chemical parameter improvement	134
Figure 5.18	Comparison of lovastatin production before and after parameters improvement	135
Figure 6.1	Time course profiles for substrate quantity in a tray system	152

Figure 6.2	Effect of substrate quantity in a tray system	155
Figure 6.3	Effect of moisture content on lovastatin formation by <i>F. pseudocircinatum</i> IBRL B3-4 in tray system	158
Figure 6.4	Effect of temperature towards lovastatin in tray system	161
Figure 6.5	Effect of inoculum size on lovastatin production in a tray system	163
Figure 6.6	Effect of pH towards lovastatin production	165
Figure 6.7	Effect of mixing frequency on lovastatin production	168
Figure 6.8	Lovastatin production and fungal growth of <i>F. pseudocircinatum</i> IBRL B3-4 in tray system after physical improvement	169
Figure 6.9	A comparison between flask and tray systems on lovastatin production and <i>F. pseudocircinatum</i> IBRL B3-4 growth	171
Figure 6.10	Chromatogram result for ratio of 7:3 (dichloromethane: ethyl acetate)	179
Figure 6.11	Chromatogram of purified lovastatin obtained from preparative TLC (A) and also an overlay of lovastatin standard with purified lovastatin	184
Figure 7.1	The fermented sample of corn grits by <i>F. pseudocircinatum</i> IBRL B3-4 displayed null appearance of beauvericin (A).	200
Figure 7.2	The detection of MON in fermented corn grits sample	201
Figure 7.3	FUM outcome displayed by UPLC system	202
Figure 7.4	<i>A. salina</i> nauplii condition after 48 hours exposure in artificial seawater (4 x 10 magnification)	203
Figure 7.5	Toxicity of fractional lovastatin against brine shrimp	204

Figure 7.6	Effect of treatment doses on female rats' body weights	207
Figure 7.7	Effect of different doses on male rats' body weights	208

LIST OF PLATES		Page
Plate 4.1	The observe and reverse view of IBRL B3-4 on different agars under light exposure.	69
Plate 4.2	The growth of IBRL B3-4 isolate under dark condition. A1-A2 are growth on PDA, B1-B2 display growth on SNA and C1-C2 are growth on CLA	70
Plate 4.3	The microscopic structures of IBRL B3-4 isolate on CLA and SNA agars under magnification of 40 x 10	75
Plate 4.4	The crucial structures of IBRL B3-4 under SEM view	76
Plate 6.1	Open column chromatography revealed 3 colour layers namely red, pinkish and yellowish	178
Plate 6.2	A view of lovastatin spots on preparative TLC obtained by fraction of 7:3 (dichloromethane: ethyl acetate)	182

LIST OF SYMBOLS AND ABBREVIATION

ANOVA	Analysis of variance
AOAC	Association of Analytical Communities
BEA	Beauvericin
CLA	Carnation leaf agar
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
FDA	Food and Drug Administration
FUM	Fumonisin
GCMS	Gas chromatography mass spectrometry
HDL	High density lipoprotein
HMG CoA	3-hydroxy-3-methyl-glutaryl-CoA reductase
HPLC	High performance liquid chromatography
IUPAC	International Union of Pure and Applied Chemistry
IVC	Individually ventilated cage
LC	Liquid chromatography
LC ₅₀	Lethal concentration 50
LDKS	Lovastatin Diketide Synthase
LDL	Low density lipoprotein
LNKS	Lovastatin Nonketide Synthase
MEGA	Molecular Evolution and Genetic Analysis
MON	Moniliformin
MS	Multiple sclerosis
NCBI	National Center for Biotechnology Information
OECD	Organization for Economic Cooperation and Development
OPA	Ortho phthaldialdehyde
PBS	Phosphate buffer saline
PCR	Polymerase Chain Reaction
PDA	Potato dextrose agar
RSM	Response surface methodology
SmF	Submerged fermentation
SNA	Spezieller Nährstoffarmer agar
SSF	Solid substrate fermentation
TBAHS	Tetrabutylammonium hydrogen sulphate
TLC	Thin layer chromatography
UPLC	Ultra performance liquid chromatography
VLDL	Very low density lipoprotein
WA	Water agar
WHO	World Health Organization
ZEN	Zearalanone
psi	Pounds per square inch
mL	Milliliter
µg/g	Microgram per gram
µl	Microliter
µg/µL	Microgram per microliter
µm	Micrometer
mg	Milligram
mg/g	Milligram per gram

mg/kg	Milligram per kilogram
rpm	Revolutions per minute
kg	kilogram
min	Minute
mm	Millimeter
v/w	Volume per weight
w/w	Weight per weight
w/v	Weight per volume
v/v	Volume per volume
°C	Degree celsius
<i>G</i>	Gravity
<i>M</i>	Molar
cm	Centimeter
nm	Nanometer
R_f	Retention factor
R_t	Retention time

LIST OF PUBLICATIONS AND CONFERENCES

a) Publications

- 1) Syarifah, A.R., Darah, I. and I Nyoman, P.A. (2013). Effect of cultural conditions on lovastatin production by *Aspergillus niger* SAR I using combination of rice bran and brown rice as substrate. *International Journal of Applied Biology and Pharmaceutical Technology*, 4(2): 150-156
- 2) Syarifah, A.R., Darah, I. and I Nyoman, P.A. (2014). Isolation and screening of lovastatin producing fungi: *Fusarium pseudocircinatum* IBRL B3-4 as a potential producer. *Journal of Pure and Applied Microbiology*, 8(3): 1763-1772
- 3) Syarifah, A.R., Darah, I. and I Nyoman, P.A. A new latent lovastatin producer viz. *Fusarium pseudocircinatum* IBRL B3-4, produced in laboratory tray system. *Pertanika Journal of Tropical Agricultural Science*, 37(4): 509-522

b) Conferences:

Oral presentation

- 1) Syarifah, A.R., Darah, I. and I Nyoman, P.A. (2010). Screening of novel lovastatin producer under solid substrate fermentation by using rice bran as a substrate and brown rice as a support material. 1st Joint Symposium of ITB and USM, Institut Teknologi Bandung Indonesia, 20-21 December 2010
- 2) Syarifah, A.R., Darah, I. and I Nyoman, P.A. (2011). A potential cooperation of rice bran and brown rice with mesophilic fungi in producing lovastatin under solid substrate fermentation (SSF). International Congress of the Malaysian Society for Microbiology (ICMSM), Bayview Beach Resort, Batu Feringgi, Penang, 8-11 December 2011
- 3) Syarifah, A.R., Darah, I. and I Nyoman, P.A. (2012). The influence of physical parameters towards hypercholesterol reducing agent production, lovastatin, under solid substrate fermentation (SSF) condition. 8th IMT-GT UNINET Bioscience Conference, Darussalam-Banda Aceh, Indonesia, 22-24 November 2012

b) Poster presentation

- 1) Syarifah, A.R., Darah, I. and I Nyoman, P.A. (2012). Assessment of double screening programmes via solid substrate fermentation (SSF) in a flask system and identification of lovastatin potential producer. 8th IMT-GT UNINET Bioscience Conference, Darussalam-Banda Aceh, Indonesia, 22-24 November 2012

**PENAMBAHBAIKAN PENGHASILAN LOVASTATIN OLEH *Fusarium*
pseudocircinatum IBRL B3-4 MELALUI FERMENTASI
SUBSTRAT PEPEJAL**

ABSTRAK

Keupayaan bran beras dan beras perang dalam menurunkan kolesterol dan menyokong sistem fermentasi substrat pepejal (SSF) tidak dapat dinafikan. Tambahan pula, kemudahan untuk mendapatkan substrat-substrat tersebut di kilang adalah mudah serta harga yang tidak mahal. Sejak beberapa tahun yang lepas, penyelidik-penyelidik telah mengkaji keupayaan padi serta komponennya yang lain seperti bran, beras, jerami dan juga sekam, mempunyai kebolehan dalam menghasilkan metabolit sekunder termasuklah statin. Hospital tempatan di Malaysia mendapat permintaan yang tinggi terhadap statin dan pengambilan lovastatin adalah yang paling ketara di mana sebanyak 51% preskripsi telah dibuat kepada pesakit-pesakit berkolesterol tinggi. Maka, kajian ini menekankan kepada penambahbaikan penghasilan lovastatin oleh *Fusarium pseudocircinatum* IBRL B3-4 melalui SSF. Bran beras dan beras perang memberikan nilai komposisi berbeza terhadap kelembapan, protein, lipid, fiber, karbohidrat dan abu. Komponen tertinggi yang didapati dalam bran beras adalah karbohidrat iaitu sebanyak $41.20 \pm 2.10\%$ manakala fiber memonopoli komposisi beras perang ($48.53 \pm 0.58\%$). Daripada jumlah 78 kulat berfilamen, 55 pencilan menunjukkan titik gelap yang positif di atas plat kromatografi lapisan nipis (TLC) dengan faktor pengekalan (R_f) antara 0.26 hingga 0.32. Walau bagaimanapun, hanya 28 pencilan kulat telah dikesan mensintesiskan lovastatin melalui menerusi sistem kromatografi cecair berprestasi

tinggi (HPLC). Pencilan IBRL B3-4 menunjukkan penghasilan lovastatin tertinggi berjumlah $281.67 \pm 44.44 \mu\text{g}$ lovastatin/g. Berdasarkan morfologi koloni dan struktur pada agar kentang dektrosa (PDA), koloni pencilan IBRL B3-4 tumbuh sehingga 54 mm dan 60 mm masing-masing di bawah keadaan gelap dan bercahaya. Untuk penelitian struktur di atas agar bunga teluki (CLA) dan agar Spezieller Nährstoffarmer (SNA), pencilan tersebut mempunyai mikrokonidia berbentuk bujur ($4.5\text{-}7.0 \times 1.7\text{-}2.6 \mu\text{m}$), makrokonidia yang melengkuk serta berbentuk sabit ($32.0\text{-}46.4 \times 1.2\text{-}2.9 \mu\text{m}$), kepala palsu, hifa berlingkar serta rangkaian pendek. Melalui pendekatan molekular pula, pencilan ini memberikan persamaan urutan sebanyak 99.33% (pangkalan data Fusarium-ID) dan 99.00% (pangkalan data GenBank) dengan *F. pseudocircinatum*. Kondisi terbaik bagi *F. pseudocircinatum* IBRL B3-4 untuk menghasilkan lovastatin dalam sistem kelalang adalah menggunakan saiz asal substrat, kandungan kelembapan sebanyak 70% (i/b), suhu pengeraman pada $30 \pm 2^\circ\text{C}$, saiz inokulum 1×10^5 spora/mL, pH 6.5, 5 g kuantiti substrat (nisbah 1:1) dengan keadaan statik tanpa pengadukan. Sistem ini juga memerlukan nutrisi tambahan iaitu 1.5% (b/b) sukrosa, 1% (b/b) ekstrak yis dan 0.5% (b/b) kalsium klorida. Sistem dulang juga memerlukan kondisi yang hampir sama dengan sistem kelalang kecuali kandungan kelembapan (60%; i/b) dan kuantiti substrat (100 g atau ketebalan 0.5 cm). Produktiviti akhir yang dikesan daripada sistem kelalang ialah $1770.00 \pm 60.00 \mu\text{g}$ lovastatin/g pepejal kering manakala dalam sistem dulang pula sebanyak $2436.67 \pm 15.56 \mu\text{g}$ lovastatin/g pepejal kering, mewakili 38% peningkatan. Kedua-dua sistem memerlukan 12 hari untuk mencapai produktiviti yang maksima. Semasa penelitian toksin kulat, *F. pseudocircinatum* IBRL B3-4 telah mensintesis moniliformin (MON) dan fumonisin B1 (FUM B1) masing-masing sebanyak $4.20 \pm 1.12 \mu\text{g}$ MON/g substrat and $1.73 \pm 0.71 \mu\text{g}$ FUM/g

substrat. Walau bagaimanapun, nilai kepekatan maut 50% (LC₅₀) untuk fraksi lovastatin menunjukkan aktiviti tidak toksik kerana nilai tersebut melebihi 1 mg/mL. Sepanjang 4 minggu, fraksi lovastatin berkepekatan 110 mg sampel fraksi/kg berat badan (yang mewakili 550 to 750 µg lovastatin/g berat kering lovastatin) memberikan dos terbaik untuk merendahkan lipoprotein ketumpatan rendah (LDL) dan meningkatkan lipoprotein ketumpatan tinggi (HDL) dalam tikus jantan dan betina Sprague dawley. Nilai akhir LDL yang dikesan melalui pembaca mikroplat Termo Saintifik Multiskan® Spektrum ialah 0.006 ± 0.001 µg/µL and 0.004 ± 0.001 µg/µL, masing-masing untuk tikus jantan dan betina. Manakala nilai HDL pula, ia meningkat menjadi 0.023 ± 0.001 µg/µL (tikus jantan) dan 0.022 ± 0.003 µg/µL (tikus betina). Keputusan yang diperolehi daripada kajian ini mencadangkan penggunaan fraksi lovastatin daripada *F. pseudocircinatum* IBRL B3-4 sebagai agen merendahkan kolesterol.

**IMPROVEMENT OF LOVASTATIN PRODUCTION by *Fusarium
pseudocircinatum* IBRL B3-4 via SOLID SUBSTRATE**

FERMENTATION

ABSTRACT

The ability of rice bran and brown rice in lowering cholesterol and supporting solid substrate fermentation (SSF) system are undeniable. Plus, the accessibility for these substrates is reachable at the mill factory with inexpensive price. For the last few years, researchers have investigated paddy and its other components like bran, rice, straw and husk, own the potentiality in producing secondary metabolite including statin. Malaysian local hospital has experienced a high demand on statin and lovastatin is the most outstanding drug with 51% prescription done for hypercholesterolemia patients. Thus, this recent investigation emphasized the improvement of lovastatin production by *Fusarium pseudocircinatum* IBRL B3-4 via SSF. Rice bran and brown rice denoted different composition values in moisture, protein, lipid, fibre, carbohydrate and ash. The highest component in rice bran was carbohydrate with $41.20 \pm 2.10\%$ while fibre was the superior composition in brown rice ($48.53 \pm 0.58\%$). Out of 78 filamentous fungi, only 55 isolates displayed positive dark spot on the thin layer chromatography plate (TLC) with retention factor (R_f) of 0.26 to 0.32. However, only 28 fungal isolates were detected to synthesise lovastatin through high performance liquid chromatography system (HPLC). IBRL B3-4 isolate depicted the highest lovastatin production with $281.67 \pm 44.44 \mu\text{g}$ lovastatin/g dry solid. Based on the colony and structural morphologies on potato dextrose agar (PDA), the colony of IBRL B3-4

isolate was grown to 54 mm and 60 mm under dark and light conditions, respectively. For structural observation on carnation leaf agar (CLA) and Spezieller Nährstoffarmer agar (SNA), the isolate owned oval shape microconidia (4.5-7.0 x 1.7-2.6 μm), slender and falcate shape macroconidia (32.0-46.4 x 1.2-2.9 μm), false head, coiled hyphae and also short chain structure. As a respond to the molecular approach, this isolate depicted 99.33% (Fusarium-ID database) and 99.00% (GenBank database) sequence similarity with *F. pseudocircinatum*. The best condition for *F. pseudocircinatum* IBRL B3-4 to produce lovastatin in the flask system was under the original substrate size, 70% (v/w) moisture content, incubation temperature of $30 \pm 2^\circ\text{C}$, inoculum size of 1×10^5 spore/mL, pH 6.5, 5 g of substrate quantity (1:1 ratio) with static condition. It also needed external nutrients namely 1.5% (w/w) sucrose, 1% (w/w) yeast extract and 0.5% (w/w) calcium chloride. The tray system also required almost the same conditions with the flask system except for moisture content (60%; v/w) and substrate quantity (100 g or 0.5 cm thickness). The final productivity detected from flask system was 1770.00 ± 60.00 μg lovastatin/g dry solid while in tray system was 2436.67 ± 15.56 μg lovastatin/g dry solid, which represented 38% increment. Both systems required 12 days incubation period to synthesis the maximal productivity. During mycotoxin investigation, *F. pseudocircinatum* IBRL B3-4 has synthesized moniliformin (MON) and fumonisin B1 (FUM B1) at 4.20 ± 1.12 μg MON/g substrate and 1.73 ± 0.71 μg FUM/g substrate, respectively. However, the lethality concentration 50% values (LC_{50}) for fractional lovastatin signified non-toxic activities as the value was higher than 1 mg/mL. Within 4 weeks treatment, fractional lovastatin concentration of 110 mg fraction sample/kg body weight (which represented 550 to 750 μg lovastatin/g dry solid of lovastatin) was slightly the best dose to reduce the low density lipoprotein

(LDL) and increase the high density lipoprotein (HDL) in male and female Sprague dawley rats. The final LDL value detected via Thermo Scientific Multiskan® Spectrum microplate readers in male and female was $0.006 \pm 0.001 \mu\text{g}/\mu\text{l}$ and $0.004 \pm 0.001 \mu\text{g}/\mu\text{l}$, respectively. While for the HDL, it amplified to $0.023 \pm 0.001 \mu\text{g}/\mu\text{l}$ (in male) and $0.022 \pm 0.003 \mu\text{g}/\mu\text{l}$ (in female). The results obtained from this work suggested the application of fractional lovastatin from *F. pseudocircinatum* IBRL B3-4 can greatly appointed this compound as an anti cholesterol lowering agent.

CHAPTER 1

INTRODUCTION

1.1 Hypercholesterolemia versus its reversal agent

Hypercholesterolemia is an anomalous cholesterol level in blood which is out of normal range and regularly welcomes the cardiovascular-relating events. Any substances or compounds which can obstruct the extra production of cholesterol in liver are recognized as hypercholesterolemia agent. Cardiovascular diseases are a cluster of heart and blood vessel abnormalities which can be controlled by cholesterol antidotes like statins. Besides anticholesterol agent, statin is also well established as a stroke preventer and able to block the peripheral vascular disease (Maron *et al.*, 2000). At the same time, it possesses biological and pleiotropic effects including antithrombotic and anti-inflammatory which may lead to atherosclerotic plaque reduction (Rosenson and Tangney 1998; Fenton and Shen 1999; Vaughan *et al.*, 2000) and also as a treatment against Alzheimer disease, multiple sclerosis, hypertension, osteoporosis, ventricular arrhythmia and immune response (Glorioso *et al.*, 1999; De Sutter *et al.*, 2000; Meier *et al.*, 2000; Chong *et al.*, 2001; Zamvil and Steinmann, 2002; Eckert *et al.*, 2005). The controllers for the hypercholesterolemia are low density lipoprotein (LDL) and high density lipoprotein (HDL). Both of these carriers are responsible to translocate the cholesterol in blood within cell which results changes in cholesterol.

1.2 Fermentation and idiolites perspectives

Fermentation is an ample process to produce complex molecules and active compounds such as antibiotics, enzymes, vitamins, amino and organic acid that are not viable to be chemically constructed (Reddy *et al.*, 2012). It is a technique of biological modification of complex substrates to become simpler compounds by microorganism including bacteria, fungi and yeast. Apart from carbon dioxide and alcohol, the metabolic breakdown also releases the additional compounds which are also known as secondary metabolites (Subramaniyam and Vimala, 2012) or idiolites. Chemical structures of these metabolites are secreted by certain microbes and some plants. They are spawned throughout trophophase period (rapid growth phase or log phase) and are further synthesized at the later phase namely iodophase (stationary phase). The accomplishment of any biosynthesis extension in iodophase relies on the tropophase (Barrios-González *et al.*, 2003). Secondary metabolism in the iodophase employs primary metabolites to generate species-specific and chemically vary end products that are not vital for microbial growth (Waites *et al.*, 2001). The booster of secondary metabolite production is when the growth is restricted due to the lack of nutrients either carbon, nitrogen or phosphate (Barrios-Gonzales *et al.*, 2003).

1.3 Lovastatin in action

Statins are the recommended drugs for hypercholesterolemia which are derived via fermentation as a secondary metabolite compound. Together with recognized diets and physical exercises, statins can be a navigator for the cholesterol level in blood. A

few statins have been manufactured as a single-ingredient products with their own commercial names by US Food and Drug Administration namely atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin (United State Food and Drug Administration, 2012). The standard recommended dose by medical practitioners was 20 to 40 mg. These drugs' concentration can deduct LDL by about 25% to 40% and increase HDL nearly 5% to 10% (Scirica and Cannon, 2005).

Lovastatin is categorized under natural statin and formerly known as mevinolin, monacolin K and Mevacor. This persuasive drug is responsible to demolish 3-hydroxy-3-methyl glutaryl coenzyme A reductase (HMG CoA) which is attracted to trap at the early step of cholesterol biosynthesis. Due to the heat and mass transfer problems which occurs in solid substrate fermentation system (SSF), submerged fermentation (SmF) has become a favorite mediator for lovastatin production (Pandey, 2003). Nevertheless, it can also be generated by the emerging technology of SSF which displays more advantages. This system promises more biotechnological benefits over than SmF even in a basic laboratory scale. It offers higher fermentation yield and product concentration packaged with better stability, lower in catabolic suppression, sterility demand (Hölker *et al.*, 2004), energy requisite, producing less dissipate water and biological friendly (Pandey, 2003). SSF has proven in exhibiting much distinctiveness which is indeed very useful and has become a major industrial microbial producer.

Production of lovastatin by SmF and SSF has been widely investigated and commonly, filamentous fungi exhibit tremendous potentiality. Reports from 2003 onwards recognized that other than *Aspergillus terreus* (Casas López *et al.*, 2004; Pansuriya and Singhal, 2010), there are numbers of different genus or species of fungi

that hold abilities to generate lovastatin specifically *Aspergillus niger*, *Fusarium* sp. (Raghunath *et al.*, 2012), *Penicillium funiculosum* (Reddy *et al.*, 2011), *Aspergillus fisheri* (Latha *et al.*, 2012), *Monascus purpureus*, *Monascus ruber* (Seraman *et al.*, 2009; Panda *et al.*, 2010), *Monascus pilosus* (Miyake *et al.*, 2006), *Aspergillus flavipes* (Valera *et al.*, 2005), *Trichoderma viridae* and *Trichoderma longibrachiatum* (Samiee *et al.*, 2003).

1.4 Rationales of Study and Objectives

Increment of hypercholesterolemia patients, high demand in statin drugs prescription, large capacity of agriculture wastes in Malaysia and advancement in SSF which can turn the waste into myriad of value added products, are the concrete rationales for this research.

An outbreak of world's bestselling drugs in 2013 which is recently highlighted by Forbes magazine exposes that hypercholesterolemia generic remedy namely statin, still holding the throne of the greatest selling drugs totaling of USD13,696 million in 2006. Until now, the number has not yet been broken by sales of any other drugs. According to the World Health Organization's report, in 2008, 30% of global deaths (equal to 17.3 million of people) are caused by cardiovascular diseases and hypercholesterolemia was the main trigger. It has been predicted that by 2030, a total mortality can potentially hit to 23.3 million figures (World Health Organization, 2013). Cardiovascular disease is one of the forefront diseases that cause death at Malaysian government hospitals in 2009. The report indicates a total of 55.9% of patients suffered

from acute coronary syndrome (ACS) due to dyslipidemia condition (an elevation of lipoprotein level which leads to hypercholesterolemia) (Ministry of Health Malaysia, 2010). A local data collection of cholesterol level among Penangites at Sungai Pinang Township indicated 3 out of 12 persons hit the cholesterol reading of 5.2 mmol/L or more (Kiew and Chong, 2013). The worrisome increases after National Cardiovascular Disease Database Malaysia (2008) reveals that the development of ACS among Malaysians is at a younger age (58) compared to other countries i.e. China, Thailand and the West (above age of 60).

Statins are a potent hypercholesterolemia modifying drug in Malaysia as 91% of discharged patients from our local hospitals have experienced the statins treatment (Wan Ahmad *et al.*, 2011; Ahmad *et al.*, 2011). The figure increases almost 19% from year 2007 to 2008. Among statins, lovastatin is the most outstanding drug in Malaysian hospitals with 51% prescription and this recent status has appointed lovastatin to be under top 40 most wanted drugs in this country. Since year 2007 to 2008, the demand towards lovastatin increased and its rank in National Cardiovascular Disease Database Malaysia changed from 13th to 9th (National Cardiovascular Disease Database Malaysia, 2008). In 2005, the expenditure of general cholesterol lowering drug (including statin) was about RM108.5 million out of RM2.2 billion of total drugs expenses (Sameerah and Sarojini, 2007). After considering all of the provided facts, Malaysians needs to have a new mode of 'drug' to lessen the government burden and obtain the healthiness. One of the best solutions is by considering the traditional or staple food which owns the medicinal value in lowering cholesterol such as 'Angkak' or red yeast rice production, an edible traditional medicinal-food for hypercholesterolemia. The trial on rice bran and

brown rice in producing anticholesterol agents are rarely being investigated especially through solid substrate fermentation system, albeit both of these products are valuable of respect in their own right. Kang *et al.* (2012) recorded a tremendous action of rice bran in reducing lipid level in mice by inspecting the lipid excretion in fecal. Even in humans, rice bran still maintains its anticholesterol greatness by improving 78% of lipid ratios in hypercholesterolemia patients (Gerhardt and Gallo, 1998). Brown rice, on the other hand, is also bringing a parallel impact as same as rice bran. Through research, a brown rice diet in *Sprague dawley* managed to put the LDL condition at ameliorate level (Roohinejad *et al.*, 2010). There was also a significant decrease in lipid activity after 10 days of lipid profile in rabbit as reported by Mohd Esa *et al.* (2011). Due to these consistent evidences, the rice bran and brown rice should release no doubt to be selected as a ruling element in SSF for the production of anticholesterol agent purpose.

In addition, the originality of lovastatin is another selection factor for this experiment. It is generated naturally from the fermentation process and holds a low adverse side effect towards animal and human (Tobert, 2003). Up until now, only about 4.6% of patients stop prescribing their lovastatin medicine because of the side effect (Goswami *et al.*, 2012). Ever since from its first discovery until the patent approval by Food and Drug Administration (FDA), lovastatin is widely produced under fermentation process and SmF is the foremost system for its production. SmF by batch or fed-batch culture is the well recognized method to generate lovastatin in the system by diversifying the conditions of physico-nutritional parameters. The advancement in SmF gives another idea to develop the SSF system. Isolation, screening, optimization, scale up system and purification of lovastatin via SmF which including Plackett-

Burman study, factorial designs and response surface methodology (RSM), are inclusively reported by researchers (Lai *et al.*, 2003; Seraman *et al.*, 2010). Thus, it is important to initiate another research of SSF lovastatin-based.

Agro-industry is still an important sector that contributes to Malaysia economical growth. In year 2013, Malaysia produced RM789.9 billion of Gross Domestic Product and out of the figure, RM56.9 billion representing agriculture, forestry and fishing sector (The Malaysian Economy in Figures, 2013). From the statistic, it can be concluded that agricultural (or agro-industry) waste becomes a troublesome burden to the government. Farmers in Malaysia habitually use an easy initiative method to overcome the biomass abundant (mostly paddy and oil palm's left-over) which is by allowing a direct open burning. Under low cost and time saving factors, the burning activity is done to clear the land and fertilize the soil for the next planting cycle. The biomass burning inspires the greenhouse gas emissions such as carbon dioxide, methane, carbon monoxide and nitrous oxide (N₂O), into the atmosphere. However, carbon dioxide is the most widely produced gas from the combustion of biomass (Mastura, 2008). The existence of those gases contribute to the production of chemicals in the ozone layer (troposphere) that directly involve in controlling the concentration of hydroxide radicals during the regulation cycle of other atmospheric gases. Some of the biomass wastes or residues can naturally be used as fertilizer, however, it involves a long decomposition process until at a certain stage it can transfer into pests' territory (Ahmad *et al.*, 2002). Some of the damped biomasses such as rice bran and palm kernel cake are also being consumed by ruminant and non-ruminant animal as a feedstuff.

The benefits offered by SSF specifically its high yield and concentrated final product with less energy requirement and effective process (Perez-Guerra *et al.*, 2003), provide some promises to disentangle all of the aforementioned problems. Hence, it directly leads into sensible reasons to proceed this experiment. The objectives of the present research are;

1. To isolate, screen and identify potential local fungi which can significantly produce lovastatin under SSF
2. To improve cultural conditions and medium compositions for lovastatin production
3. To compare lovastatin production in flask and laboratory tray systems
4. To purify lovastatin via chromatographic purification
5. To test the effectiveness of fractional lovastatin as cholesterol lowering agent on laboratory animal, Sprague dawley rats.

CHAPTER 2

LITERATURE REVIEW

2.1 Agricultural crops in Malaysia: Rice processing and its byproduct

In a year, a total of 998 million tones of agricultural wastes are produced worldwide and out of the number, 1.2 million tones is represented by Malaysia alone (Twana and Fauziah, 2012). According to the Department of Statistic Malaysia, in 2010, the oil palm sector conquers the landfill agricultural production with 64,282,738 tones of fresh fruit bunches followed by paddy (2,464,831 tones), cocoa (402 tones) and rubber (56 tones).

The world needs to support 600 million tones production of *Oryza sativa* (rice) yearly (Chen *et al.*, 2012) and 150 million hectares of land area are preserved for paddy planting (Food and Agriculture Organization, 2004). Rice has a few layers namely hull, bran layer, endosperm and embryo. Once the outer layer (the hull or husk) is eradicated, it will expose the brown rice which is the carrier of the essential nutrients. Rice is a staple food for Asian but the grain polishing process has eliminated a lot of nutrients richness. Cleaning, hulling and post-hulling processing which cover whitening, polishing and grading procedures are the basic steps in rice refining (Mohd Esa *et al.*, 2013). Those programs destroy B1, B3 and B6 vitamins at 80%, 67% and 90%, respectively. Others ousted minerals are half of manganese and phosphorus with 60% iron and all of the dietary fiber and vital fatty acid (Babu *et al.*, 2009).

The main outcome of rice process is endosperm or rice with 70% production which excludes its minor portion (20% rice husk, 8% rice bran and 2% rice germ)

(Wells, 1993; de Deckere and Korver, 1996; Van Hoed *et al.*, 2006). A hundred kilograms of paddy equal to 56 to 58 kg white rice, 10 to 12 kg broken rice, 18 to 20 kg hull or husk and 10 to 12 kg rice bran (Kahlon, 2009). Rice husk and bran are the only leftovers that are applied into feed formulation (Department of Veterinary Services, 2013).

Comparing to the white rice, brown rice is claimed to be the best rice to consume. Within the brown rice, there is a bran layer and it is composed of pericarp, seed coat, nucellus and aluerone layer (Tahira *et al.*, 2007). Brown rice becomes the second choice because of low eating quality and poor in palatability. The hard and dark cooked grain which is originated from the bran contributes to difficulty during munching process. But yet, those two elements (bran and brown rice) are the best options for healthy diets.

2.2 Cholesterol: a review

Cholesterol is vital during essential bile acids secretion and also very low density lipoproteins (VLDL) production for hormone biosynthesis. Generally, it is a fat substance or steroid molecule which is accumulated in our blood and cells. One-third of body cholesterol (75%) originated via diet and the other two-thirds (25%) are naturally generated from intracellular precursors by organs (Albert *et al.*, 1980; Demain 1999; Furberg 1999). Cholesterol comes in two main packages; the bad cholesterol LDL and the good cholesterol HDL. The emergence of extra LDL in blood commonly relates to the increasing risk of heart attack and stroke. By contrast, HDL becomes a life guard

against those diseases. Besides genetic heritage, lifestyle and diet, the accumulation of cholesterol around the arteries is also depending on age factor (Scirica and Cannon, 2005). The animal-based food such as meats, poultry and dairy products and also some seafood are sources for exogenous cholesterol ingestion with 30% to 75% naturally absorbed by human body. For endogenous synthesis, it takes place in liver and spares 600 to 1000 mg/day cholesterol for our body usage. About 750 to 1250 mg cholesterol are secreted each day in bile. Generally, cholesterol and other fats cannot directly suspend in blood. Thus, it has to be carried by its own transporter, HDL and LDL. *In vivo*, cholesterol synthesis is triggered from acetyl CoA, reacts with acetoacetyl CoA to form HMG CoA and then it is narrowed down to mevalonate with HMG CoA reductase intervention (Campbell and Farrel, 2008). During this rate limiting step, the invading of cholesterol inhibitors such as statins are very crucial in controlling cholesterol over production.

2.2.1 Biomedical applications of lovastatin

Cholesterol obstruction by lovastatin not only works on hypercholesterolemia but also in other clinical terms. The trafficking condition during or after the elimination of HMG CoA reductase in cholesterol biosynthesis pathway (specifically in mevalonate pathway) allows bunch of mystifying pathways with unknown mechanisms system that might spare a lot of advantages in healing other chronic diseases.

2.2.1.1 The triumph of lovastatin in heart diseases

Human heart is a pump that comprises four chambers with remarkable ‘lup-dup’ rhythm, symbolic of the opening and closing of its valves. A complete blood pumping travels from right ventricle to left ventricle via pulmonary artery and pulmonary vein and finally, the oxygenated blood will be transported throughout the body by arteries. This tremendous process repeats around 72 times in a minute, more than 100,000 times daily, over 37 million times yearly and almost 3 billion times in a lifetime. Approximately, the human heart pumps 4,000 gallons of blood per day. The hard work of heart may welcome variety of diseases and usually the blood vessels become the main factor of the problematic compare with the heart itself. The failure of coronary arteries to transport blood and oxygen required by the heart muscle is defined as coronary heart disease and the most widespread cause of this disease is atherosclerosis. The event happens due to the plaque attachment to the coronary arteries wall and obstructs the blood flow. The plaque is built of cholesterol deposit, calcium and anomalous cells (Pampel and Pauley, 2004). The lovastatin intakes can increase the good cholesterol level (HDL) in blood system which leads into lesion retardation around the artery. Furthermore, it is also believed to cure all kinds artery related problems including improvement of endothelial function, controlling the inflammatory responses, sustaining plaque constancy and averting thrombus development (Sreenivasan *et al.*, 2008).

2.3 Statins

2.3.1 Back to the past: the historical statins

Akira Endo is the best person to enlighten the discovery of statins. In 1971, a research team was set up to isolate fungi and mushrooms. Within two years, they managed to identify *Penicillium citrinum* ML-236B as a mevastatin or compactin producer, an inhibitor for lipid secretion. Pioneering in statin group, mevastatin scientifically denoted a reduction of plasma cholesterol in hens, dogs and monkeys. However, Japan stopped the trial because of the tumor detection in dogs. The next finding is a ‘controversy’ lovastatin. In Tokyo (February 1979), Endo has isolated mevastatin analogues from *Monascus ruber* namely monacolin K, monacolin J and also monacolin L. Within those compounds, monacolin K generated the major product and vaguely indicated better result in demolishing HMG CoA reductase compared with the original mevastatin. Those three derivatives (monacolin K, monacolin J and monacolin L) are patented by the owner in February, April and October 1979, respectively (Endo, 2004). Meanwhile, in 1978, Alfred Alberts and Julie Chen from Merck Research Laboratory found a new soil fungus, *Aspergillus terreus* which can also produced HMG CoA inhibitor. They called it mevinolin but later it is officially launched as lovastatin (Tobert, 2003). Merck formally patented mevinolin in June 1979 and four months later, it is verified that monacolin K and mevinolin consisted the same structure. Mevinolin is found earlier than monacolin K (November 1978 versus February 1979), but the copyright was four months behind monacolin K (June 1979 versus February 1979). There is no toxic revealed by this compound during toxicity test on animal and via this result, Merck boldly continued the clinical test on hypercholesterolemia patients. The

trials exposed a significant drop of plasma cholesterol with slight side effects. On November 1986, Merck moved one step forward by submitting an application to the Food and Drug Administration (FDA) for lovastatin commercialization. The FDA committees signed an approval on 1 September 1987 with a condition. The drug can be prescribed to the patients only if the diet or non-pharmacological techniques can not lessen the overproduction of cholesterol in blood (Merck and Co., 1987).

Basically, statins are built up of polyketide portion (hydroxyl-hexahydro naphthalene ring system) initiated from acetate units bonded together in a head-to-tail formation (Manzoni and Rollini, 2002). Native lactone (a close ring form) and β -hydroxyl acid (open ring form) are two major forms of statins. After mevastatin failure (compactin) and successful medicinal effect of lovastatin, statins welcoming a new comer into the cluster namely simvastatin (or Synvinolin and Zocor). It contains the same molecular structure as lovastatin but with the additional side chain methyl group. Then, the world witnessed the existence of pravastatin followed by fluvastatin, atorvastatin, cerivastatin and recent finding in 2003, rosuvastatin. As mentioned earlier, statins are triggered from fermentation. Thus, all of the statins are huddled into natural, semisynthetic and synthetic. Mevastatin and lovastatin are certainly natural statins while simvastatin is categorized under semisynthetic as it is synthesized from lovastatin by replacing the 2-methylbutryl side chain with 2,2-dimethylbutyryl. Pravastatin undergoes a biological transformation from mevastatin which involves *Streptomyces carbophilus* during the process. Other new statins members such as fluvastatin, atorvastatin, pitavastatin and rosuvastatin are in synthetic cluster. Even statins share a general action mechanism and structural composition which are very identical to HMG portion, they

diverge in their chemical structures (Figure 2.1). These structures are very potent in showing affinity towards HMG CoA reductase. The differences of each statins lie in the hydrophobic components which covalently tie a linkage to HMG-like moiety. In synthetic class, they have fluorophenyl groups to link to the structure. Decalin ring substituent appears in naturally derived statins and a special case for pravastatin as it consists a hydroxyl substituent at the hexahydronaphthalene nucleus which is considered as hydrophilic (Nigović *et al.*, 2012).

2.3.2 Biosynthesis of lovastatin

The IUPAC name of lovastatin is [(1S,3R,7R,8aS)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-oxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl](2S) 2-methylbutanoate with empirical formula of $C_{24}H_{36}O_5$ and 404.55 molecular weight. It is a white, nonhygroscopic crystalline powder which is unsolvable in water except in ethanol, methanol and acetonitrile (Goswami *et al.*, 2012). Lovastatin is consumed as lactone prodrug which is transformed into active HMG CoA inhibitor form (hydroxyl acid) in the hepatocyte organ, liver. As noted above, all statins derived via acetate units to structure out polyketide skeleton. Lovastatin Nonketide Synthase (LNKS) and Lovastatin Diketide Synthase (LDKS) are two polyketides preserved for lovastatin in Polyketide Synthase system (Barrios-González and Miranda, 2010). By referring to previous study by Endo (1979), two main chains are involved to spawn monacolin K or lovastatin which are monacolin J and monacolin L. Figure 2.2 designates the first synthesised chain of monacolin L which is constituted of nine acetate molecules and

then it alters into monacolin J (assemble from two units of acetate and nine methionine units) under hydroxylation process. Monacolin J subsequently linked to methyl butyryl CoA lovastatin which is assembled from two acetate units and one methionine unit. Polyketide Synthase system codes the LNKS and LDKS in *Aspergillus terreus* with a few essential genes engaged; *lov B*, *lov C*, *lov F* and *lov D*. LNKS is a gene outcome of *lov B* that interacts with *lov C* (enoyl reductase) to perform dihydro monacolin L which is next synthesised into monacolin J. The other pathway to generate monacolin J is via LDKS system and it is a prominent key to guarantee an efficient production of lovastatin. *lov F* cooperated with *lov D*, a transesterases enzyme, which allow the attachment of 2-methylbutyric acid to monacolin J and proceed to the formation of monacolin K or lovastatin (Manzoni and Rollini, 2002; Sreevanivasan *et al.*, 2008; Barrios-Gonzales and Miranda, 2010).

2.3.3 Lovastatin in SSF

Low cost factor due to dual-duty of solid substrate (as a matrix and nutrients support) is the utmost reason for SSF selection. One of the ancient uses of SSF, which dates approximately at the first century A.D., is angkak (also known as anka or Chinese red rice) production by *Monascus* sp. At that time, in China, Angkak production was secretly produced. However, during Ming Dynasty (A.D 1368-1644), this medicinal-value rice was widely published to treat a lot of diseases including colic dyspepsia, diarrhea, hangovers and bruised muscles. Besides, it is also consumed by Chinese to improve the blood circulation and upgrading the spleen and stomach function




Figure 2.1: Different structures of natural, semisynthetic and synthetic statins and its similarity with HMG portion of HMG CoA reductase (Manzoni and Rollini, 2002)




Figure 2.2: Biosynthesis pathway for lovastatin generation in simplified scheme. The different enzymes that impregnated their own specific genes are actively involved in every part of bioconversion (Manzoni and Rollini, 2002).

(Arunachalam and Narmadhapriya, 2011). According to recent studies, single and co-culture inoculation (Panda *et al.*, 2009; Panda *et al.*, 2010) of *Monascus* sp. initiates the activity of lovastatin which indirectly proves that *Monascus* sp. fronting the lovastatin production in SSF compared with other filamentous fungi. Szakacs *et al.* (1998), Valera *et al.* (2005), Wei *et al.* (2007), Pansuriya and Singhal (2010), Reddy *et al.* (2011) and Latha *et al.* (2012) are researchers who gave their efforts in investigating the best lovastatin producers among filamentous fungi under SSF condition. It includes the mutant or wild-type species of suspected fungi. Furthermore, studies on maximizing the production of secondary metabolite lovastatin is started to be emphasized via response surface methodology (RSM), Plackett-Burman, Box-Behnken factorial and as well as fabrication and modeling of bioreactor designs.

2.4 Solid substrate fermentation (SSF) and its consideration factors

2.4.1 Definition of SSF

Solid substrate fermentation is a general term in describing any fermentation process which involves solids including suspensions of solid particles in an unremitting aqueous phase and even trickle filters. Solid state fermentation is also categorized under solid substrate fermentation (Mitchell *et al.*, 2006). It is characterized as growing microorganism on adequate moist of solid supports which are comprised of insoluble natural substrates and inert carriers (Hölker *et al.*, 2004). A natural territory is created by allowing the absence or near absence of free water in the fermentation process (Pandey *et al.*, 2000). Throughout this experiment, SSF term is used to represent solid

substrate fermentation. As reported by Pandey (2003), the selection of microorganism and substrate, physico-chemical parameters, isolation and purification of the product are some critical aspects that should be considered prior to SSF employment.

2.4.2 Rationale of filamentous fungi selection

Common microbes such as bacteria, yeast and fungi are capable to grow and conquering the solid substrate. However, the most highlighted microbe in SSF, especially the ones with lovastatin-producing ability, goes to fungi kingdom. By considering the physiological, enzymological and biochemical properties in a low water activity (A_w) event in SSF, filamentous fungi are the best selection compared with the other unicellular microorganisms (Raimbault, 1998; Pérez-Guerra *et al.*, 2003).

Two gigantic groups in macro fungi are Ascomycetes and Basidiomycetes. However, only a few of the members can synchronize their growth with SSF surroundings (Hölker *et al.*, 2004). The hallmark of filamentous fungi is its special hyphae with enzymatic tip. The hyphae ability in elongating, branching and attacking the substrate has made this microorganism more superior in host colonisation and nutrients utilisation (Figure 2.3). After inoculation process, spores take 10 hours to germinate. At this time, the substrate bed has to supply some heat to make sure a precise temperature for smooth germination. This progress results in daughter hyphae production which induces new branches and finally expanding the micro colony. Elongation of hyphae stimulates the micro colonies meeting which welcome a negative interaction between hyphae tips. Such this incident forces the tips to change their route




Figure 2.3: The illustrations of filamentous fungi growth invading the substrate matrix during fermentation process (Rahardjo *et al.*, 2006).

or retarding the growth. For those that keep on extending, they can choose to grow at the surface of the liquid film or injecting into the matrices (Mitchell *et al.*, 2006). Hyphae are grown in linear and constant pattern to permit a contact to the cell wall of solid substrate. Once it grips the substrate, the hyphal apex emits an amount of hydrolytic enzyme to ensure a smooth penetration into the substrate. Unlike SmF, the enzyme excretion in SSF is more concentrate and contribute a lot in penetration efficiency. Other than invading the host, a close connection between hyphae and substrate also encourage biological synthesis and fungal metabolic activities (Raimbault, 1998) like secondary metabolites production.

2.4.2.1 *Fusarium* sp. and its major mycotoxins

This genus is defined as plant destructor with pan-tropical distribution via air, seeds, soils or plant debris. Commonly, the members of this genus are actively contributed in economic losses involving cereal grains (Goswami and Kistler, 2004), vascular wilts on banana (Liew *et al.*, 1998), bakanae on rice (Nur Ain Izzati, 2007), pokkah boeng on sugarcane (Siti Nordahliawate, 2007), root rots on vegetable such as asparagus (Al-Amodi and Salleh, 2005) and some researchers reported cankers production on soft and hardwood trees (Wingfield *et al.*, 2008).

This species is literally divided into three clades; African, American and Asian. According to the hypothesis of O'Donnell *et al.* (1998), the originality of fungi host including its evolvement should be taking into account during clade clustering. However, numbers of species composition does not suit with the hypothesis. Among

these three groups, African is announced as the biggest clade which has 23 phylogenetic lineages and it huddles as productive chlamyospore-formers. The so-called ‘American clade’ has 18 phylogenetic lineages while the Asian is the smallest clade with 10 phylogenetic lineages (Kvas *et al.*, 2009).

Mycotoxins are classified as unavoidable natural contamination in most of foods and feeds. Fumonisin (FUM), zearalenone (ZEN), moniliformin (MON) and beauvericin (BEA) are the most regular toxins produced by *Fusarium* sp. (Logrieco *et al.*, 2002; Leslie *et al.*, 2004; Sopterean and Puia 2012). The sodium or potassium salt of 1-hydroxycyclobut-1-ene-3,4-dione (Figure 2.4) is the precise criterion to elaborate moniliformin (MON). Its first outbreak was in 1973 after the extraction process of *F. proliferatum* which was inoculated in a corn culture. However, the identified species shown a similar characteristic with *F. moniliforme*, thus the mycologists came out with moniliformin name (Cole *et al.*, 1973). At least 30 *Fusarium* species produce this compound in the cereal grains (commonly corn) and the most influential species are *F. proliferatum* and *F. subglutinans*.




Figure 2.4: The skeleton structure of moniliformin (sodium salt) (Munimbazi and Bullerman, 2001)

This metabolite is very toxic either to plants or animals. The symptoms of afflicted animal may be varied and commonly muscular failing, respiratory suffering, cyanosis, coma and also death, are the ordinary signs. Analyte that contains moniliformin has to go through cleanup process before it is further analysed via liquid chromatography, capillary electrophoresis or immunochemical reactions (Munimbazi and Bullerman, 2001).

Fumonisin is named after *F. verticilloides* which previously known as *F. moniliforme*. It comprises B₁, B₂ and B₃ and commonly B₁ is found at the highest level compared with others (Marasas, 1996). (Rheeder *et al.*, 2002). Approximately, 70 to 80% of the total fumonisins are represented by FUMB₁ and FUMB₂ reaches up 15 to 25%. The FUMB₃ produces the lowest level which is around 3 to 8%. These percentages occur in solid or liquid medium condition (Branham and Plattner, 1993; Marín *et al.*, 1995). Fumonisin B₂ (FUMB₂) and fumonisin B₃ (FUMB₃) show up after the finding of FUMB₁ in 1988. The backbone of FUMB₂ and FUMB₃ are lacked in free hydroxyl groups compared with FUMB₁ (Figure 2.5) (Plattner *et al.*, 1992).

The detection of FUMB₁ in a sample usually is done via liquid chromatography (LC) completed with fluorescence detector. This toxin contains a least UV-light absorbing chromophore and has no fluorescence production because of the simple long chain alcohols, thus a derivatization of the free amine is required for detection purpose (Shephard *et al.*, 1990; Kedera *et al.*, 1999).

There are a few of diseases related to fumonisins such as leukoencephalomalacia (ELEM), pulmonary oedema syndrome (PES) and hepatocarcinoma. These diseases